Project Grant R01NS138604
Award Date
4/15/25
Completion Date
2/28/30
Dollars Obligated
$738K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the development of novel epigenetic editing tools to treat Rett syndrome, a devastating neurodevelopmental disorder.
The $698,459 award to Epitor Therapeutics, Inc. will fund the optimization of an epigenetic editor combining a compact CRISPR-based DNA targeting...
This $522,500 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) supports research to investigate the role of astrocytes, a type of brain cell, in Rett syndrome.
The key focus is to determine if correcting the altered release of specific astrocyte-secreted proteins, particularly the class 3 semaphorin Sema3C, can ameliorate Rett...
This $398,750 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research to investigate mitochondrial dysfunction in human astrocytes with Rett syndrome-causing MECP2 mutations.
The primary research objectives are to: 1) Identify common aberrations in gene expression related to mitochondrial function in human astrocytes bearing different...
This $125,162 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the role of heat shock signaling in Rett syndrome, a neurodevelopmental disorder associated with MECP2 gene mutations.
The research aims to 1) determine if genetically or pharmacologically modulating the heat shock response can mitigate Rett syndrome...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is funding research to investigate motor coding and dysfunction in Rett syndrome. The $450,000 award to the University of Arkansas, Fayetteville aims to leverage high-dimensional geometry to better understand how Rett syndrome, caused by disrupted MECP2 gene function, leads to motor...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) provides $153,368 to Loyola University of Chicago's Health Sciences Campus Division to develop a novel strategy using locked nucleic acid (LNA) site-blocking antisense oligonucleotides (SBAOs) to increase expression of the MECP2 gene. The goal is to reverse symptoms of Rett syndrome, a neurodevelopmental...
This $564,186 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) seeks to investigate how a specific genetic mutation (PACS2E209K) associated with a neurodevelopmental disorder known as PACS2 syndrome impacts neuronal metabolism and neurotransmission. The research, to be conducted at the University of Pittsburgh, will utilize advanced live-cell...
This federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), provides $1,671,258 to Yale University to develop engineered neuronal-specific therapeutic mRNA treatments for Rett syndrome. The award has a performance period from December 15, 2024 to December 14, 2026. As the prime grantee, Yale University will conduct research and development activities to advance therapeutic approaches for this neurological...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to develop a new therapy for neurodevelopmental mitochondrial disorders. The $105,625 award, with a period of performance from August 1, 2024 to July 31, 2026, will support research to: 1) analyze how a specific succinyl-CoA precursor is metabolized in a mouse model of pyruvate dehydrogenase...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $160,500 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports research to investigate the epigenetic mechanisms underlying neurodevelopmental defects in Menke-Hennekam Syndrome, a rare genetic disorder caused by mutations in the EP300 gene. The project aims to (1) identify maturation...